ALXO News and Press, ALX Oncology Holdings Inc. From 12/17/21

Indie Semiconductor (INDI -5.4%) shares plummets after the company disclosed a sale of shares by CFO Thomas Schiller. Thomas Schiller sold 200,00 shares of the company's common stock at $11.85 for $2.4M. Form 4 A look at INDI's ownership composition: For further details see: I...

ALX Oncology (ALXO -6.6%) shares plummets after the company disclosed a sale of shares by director Jason Lettmann. Lettmann sold 387,345 shares of the company's common stock at $25.01 - $30.29 in a series of transactions, worth ~$75M. Form 4 A look at ALXO's ownership composition: A...

The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event. For further details see: ALX Oncology (ALXO) Presents At 63rd Annual Meeting of ASH - Slideshow

DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia PR Newswire CUPERTINO, Calif. , Dec. 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its boar...

ALX Oncology (ALXO -25.1%) shares have plunged after the company disclosed a sale of shares by director Jason Lettmann. Lettmann sold 145,637 shares of the company's common stock at $30.12 - $33.92 in a series of transactions, worth ~$4.7M. Form 4 A look at ALXO's ownership composition: Learn...

Gainers: Nuverra Environmental Solutions (NYSE:NES) +88%. Arena (NASDAQ:ARNA) +82%. BELLUS (NASDAQ:BLU) +56%. Foghorn Therapeutics (NASDAQ:FHTX) +43%. Petros Pharmaceuticals (NASDAQ:PTPI) +45%. Biofrontera (NASDAQ:BFRI) +29%. Mawson Infrastructure Group (OTCQB:MIGI) +17%. Reliance Global Grou...

Gainers: Arena Pharmaceuticals (NASDAQ:ARNA) +84%, BELLUS Health (NASDAQ:BLU) +68%, Foghorn Therapeutics (NASDAQ:FHTX) +37%, Petros Pharmaceuticals (NASDAQ:PTPI) +27%, Tabula Rasa HealthCare (NASDAQ:TRHC) +23%. Losers: IGM Biosciences (NASDAQ:IGMS)...

-- Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk MDS -- Objective responses were observed in patients with relapsed/refractory MDS that had progressed after pr...

ALX Oncology is developing a novel CD47 inhibitor and has differentiated itself from its competitors with its approach. Recent data updates have reaffirmed my original thoughts of their likelihood of success in several indications. I was previously neutral on ALX Oncology, given t...

The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event. For further details see: ALX Oncology Holdings (ALXO) Investor Presentation